An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy

Chang Sue Yang, Joseph A. Khawly, Dean P. Hainsworth, San Ni Chen, Paul Ashton, Hong Guo, GknnfJaJfe

Research output: Contribution to journalArticle

98 Scopus citations

Abstract

Objective: To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR). Methods: The therapeutic efficacy of the TA/5-FU codrug was determined in a rabbit model that simulates human PVR. Intravitreal levels of triamcinolone and 5-fluorouracil were measured at different time points and drug release in vitro was tested. Toxic effects were evaluated by electroretinograpy, clinical examination, and light microscopy. Results: Both the severity of PVR grade and the percentage of eyes with moderate or worse tractional detachment were significantly less in eyes treated with the codrug. The therapeutic effect of the intravitreal codrug was paralleled by sustained intravitreal levels of triamcinolone and 5-fluorouracil. There were no drug-related toxic effects evident on clinical or histopathologic examination of eyes containing the TA/5-FU codrug. Conclusions: The intravitreal sustained-release TA/5-FU codrug effectively inhibits the progression of PVR in a rabbit model that closely resembles PVR in humans. The TA/5-FU codrug may simultaneously target different components of the wound-healing response.

Original languageEnglish (US)
Pages (from-to)69-77
Number of pages9
JournalArchives of Ophthalmology
Volume116
Issue number1
DOIs
StatePublished - 1998

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy'. Together they form a unique fingerprint.

Cite this